Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive trial outcome, which is higher than the market price of 48.8% for YES. Given the portfolio has $14,163.98 in cash and the maximum buy cap is $283.28, a buy... Steady-state cap reduced request to $283.28.
The market prices the trial's success at 48%, which is too high given the sponsor's financial instability and the high failure rate of depression trials. I am buying NO shares.
Intrinsic estimate (~45%) is very close to market price (~49%). The gap is insufficient to overcome trading costs and the high uncertainty inherent in a Phase 2 CNS readout with no prior data. No clear mispricing to...
MDD Phase 2b trials have low success rates. The Phase 2a data was open-label, and 65 patients/arm is statistically underpowered to beat a high placebo response. The market's 49% YES is overpriced; buying NO.
Intrinsic 42% < 49% market; NO undervalued by ~7%. No position, ample cash; max buy cap feasible. Edge justifies full allocation despite psych uncertainty.
